/

KALA

KALA BIO, Inc.Closed

0.2600−0.02 −7.14%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.2762 +6.23%

Open

0.2850

Prev close

0.2800

Day range

0.26000.2850

52-week range

0.260095.50

Volume

422.30K0.29×

Mkt cap

5.03M

P/E ttm

—

Fwd P/E

-0.04

EPS ttm

-10.71

Div yield

0.00%

Earnings

—

From 52w high

−99.73%

Price Chart

Yahoo Finance · delayed

KALAOct 13, 2026O 0.2850H 0.2850L 0.2590C 0.2600−0.0200 (−7.14%)Vol 425.20K

SMA 500.6089
SMA 2008.8095

1Y change −99.65% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

KALA KALA BIO, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −28.57%
1 month: −54.55%
3 months: −73.00%
6 months: −97.70%
Year to date: −99.06%
1 year: −99.65%

Valuation & ownership

Market cap: 5.03M
Enterprise value: −2.20M
P/E (ttm): —
Forward P/E: -0.04
PEG ratio: —
Price / book: 0.56
Price / sales (ttm): —
EV / EBITDA: 0.09
EPS (ttm): -10.71
EPS (forward): -6.67
Beta (5y monthly): -2.41
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 19.34M
Float: 19.34M
Short % of float: 7.06%
Short ratio (days): 0.37
Held by insiders: 1.24%
Held by institutions: 4.07%
Avg volume (3m): 1.48M
50-day average: 0.6194
200-day average: 8.97
52-week change: −99.65%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 23.2
vs 50-day SMA: −57.30%
vs 200-day SMA: −97.05%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 23.84%
Realised vol (20d, ann.): 126.6%
From 52-week high: −99.73%
From 52-week low: +0.39%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About KALA BIO, Inc.

Yahoo Finance profile

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 6
Headquarters: Arlington, MA, United States
Website: kalarx.com
Officers: Ms. Mary Reumuth CPA Treasurer & Secretary
Mr. Avi Minkowitz CEO, CFO & Chairman
Dr. Justin Hanes Ph.D. Founder & Chair of the Scientific Advisory Board
Ms. Jill S. Steier Executive Director of Investor Relations & Corporate Communications

SEAS

Seasonality · KALA

2017–2026 · monthly returns

Strongest month Dec +56.98%Weakest month Sep −25.80%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-4.7	-28.3	-54.5	-39.3	-57.5	-22.4	-56.3	-11.0	-36.3	-39.4			−99.1%
2025	32.6	-24.7	-17.3	-30.7	-6.3	28.0	42.2	65.7	-86.4	-49.0	23.8	-42.4	−92.0%
2024	-0.7	3.3	11.0	-14.4	-1.5	5.5	-8.3	-10.0	-2.6	23.5	-2.6	1.2	−0.9%
2023	-54.5	-41.6	48.6	4.8	-9.3	2.0	3.0	-10.7	-33.7	-22.5	-12.3	15.7	−81.7%
2022	-26.9	-25.2	108.5	-52.9	-46.5	-13.8	10.0	-7.9	-27.3	-42.5	-16.7	621.2	−36.9%
2021	9.6	-0.3	-9.0	14.7	-26.9	-6.2	-34.9	-2.0	-22.5	-33.6	9.2	-36.3	−82.2%
2020	61.5	-10.2	64.3	13.3	23.6	-14.6	-16.7	1.7	-15.7	-12.0	13.0	-9.1	+83.7%
2019	13.1	51.7	-1.4	-6.2	-28.7	15.4	-7.8	-30.1	-7.4	-4.6	14.9	-11.5	−24.5%
2018	-17.7	-7.7	12.7	-5.1	1.5	-9.9	-7.6	6.5	-26.9	-26.5	-13.1	-22.4	−73.6%
2017								26.0	-9.7	-29.7	19.2	-3.4	−7.9%

INSD

Insider Activity · KALA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

27.78M shares

Sells, 6 months

5.13M shares

Net shares

+22.65M

Net change in insider shares

−101.10%

Date	Insider	Transaction	Shares	Value
Oct 22, 2025	Reumuth MaryChief Financial Officer	Sale at price 0.82 - 0.83 per share.	33.2K	$27.54K
Oct 22, 2025	Iwicki Mark T.Director	Sale at price 0.81 per share.	154.9K	$125.46K
Oct 21, 2025	Kharabi DariusOfficer	Sale at price 0.83 per share.	20.8K	$17.27K
Oct 21, 2025	Brazzell Romulus KimOfficer	Sale at price 0.83 per share.	46.7K	$38.80K
Oct 21, 2025	Bazemore Todd MDirector	Sale at price 0.83 per share.	47.8K	$39.65K
Sep 30, 2025	Baker Bros Advisors, L.P.Former	Sale at price 1.38 - 1.60 per share.	730.4K	$1.06M
Jun 23, 2025	Reumuth MaryChief Financial Officer	Sale at price 4.01 per share.	3.6K	$14.56K
Jun 23, 2025	Kharabi DariusOfficer	Sale at price 4.01 per share.	4.5K	$18.09K
Jun 23, 2025	Iwicki Mark T.Director	Sale at price 4.01 per share.	13.2K	$53.04K
Jun 23, 2025	Bazemore Todd MChief Executive Officer	Sale at price 4.01 per share.	4.1K	$16.27K
Jun 12, 2025	Farid MarjanDirector	—	2.5K	—
Jun 12, 2025	Perry Gregory DDirector	—	2.5K	—
Jun 12, 2025	Koven Andrew IanDirector	—	3K	—
Jun 12, 2025	Rosen Howard BDirector	—	2.5K	—
Jun 12, 2025	Iwicki Mark T.Director	—	2.5K	—
Jun 12, 2025	Myers Charles DanielDirector	—	2.5K	—
Jun 2, 2025	Reumuth MaryChief Financial Officer	Sale at price 3.74 per share.	2.9K	$10.66K
Jun 2, 2025	Kharabi DariusOfficer	Sale at price 3.74 per share.	730	$2.73K
Jun 2, 2025	Brazzell Romulus KimOfficer	Sale at price 3.74 per share.	3.7K	$13.79K
Jun 2, 2025	Iwicki Mark T.Director	Sale at price 3.74 per share.	10.9K	$40.64K

KALA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

KALA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About KALA BIO, Inc.

Seasonality · KALA

Insider Activity · KALA

Congress Trades · KALA

Investors Holding KALA

Investors Holding KALA

Congress Trades · KALA

Insider Activity · KALA

Seasonality · KALA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About KALA BIO, Inc.

Earnings & Dividends

News